试用视觉搜索
使用图片进行搜索,而不限于文本
你提供的照片可能用于改善必应图片处理服务。
隐私策略
|
使用条款
在此处拖动一张或多张图像或
浏览
在此处放置图像
或
粘贴图像或 URL
拍照
单击示例图片试一试
了解更多
要使用可视化搜索,请在浏览器中启用相机
Rewards
English
全部
图片
灵感
创建
集合
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
自动播放所有 GIF
在这里更改自动播放及其他图像设置
自动播放所有 GIF
拨动开关以打开
自动播放 GIF
图片尺寸
全部
小
中
大
特大
至少... *
自定义宽度
x
自定义高度
像素
请为宽度和高度输入一个数字
颜色
全部
彩色
黑白
类型
全部
照片
插图
素描
动画 GIF
透明
版式
全部
方形
横版
竖版
人物
全部
脸部特写
半身像
日期
全部
过去 24 小时
过去一周
过去一个月
去年
授权
全部
所有创作共用
公共领域
免费分享和使用
在商业上免费分享和使用
免费修改、分享和使用
在商业上免费修改、分享和使用
详细了解
重置
安全搜索:
中等
严格
中等(默认)
关闭
筛选器
5111×3407
www.centerforbiosimilars.com
FDA Issues CRL for Biocon Biologics, Viatris Avastin Biosimilar
6000×3750
www.centerforbiosimilars.com
Report: Policy Changes Needed to Ensure Long-Term Market Stability for ...
6700×4467
www.centerforbiosimilars.com
FDA Approves Epysqli as Second Soliris Biosimilar
4000×2667
www.centerforbiosimilars.com
Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switc…
3600×2313
www.centerforbiosimilars.com
Study: Liraglutide Biosimilar RD12014 Demonstrates Biosimilarity to Victoza
5878×3919
www.centerforbiosimilars.com
IQVIA Report Flags Challenges With Biosimilar Access, Savings ...
4592×3064
www.centerforbiosimilars.com
Webinar: Experts Discuss Avenues to Improve Biosimilar Developmen…
1200×630
www.centerforbiosimilars.com
Fresenius Kabi Launches Stimufend in the US
3840×2638
www.centerforbiosimilars.com
Switch to Adalimumab Biosimilar Safe, Effective for Uveitis, but the ...
3840×2152
www.centerforbiosimilars.com
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023 ...
5760×3840
www.centerforbiosimilars.com
Overview of Trastuzumab Biosimilars in HER2-Positive Breast Cancer
1816×1177
www.centerforbiosimilars.com
How can we achieve a long-term sustainable biosimilars market?
3200×2133
www.centerforbiosimilars.com
No Differences in Treatment Persistence, Safety Detected fo…
4267×2133
www.centerforbiosimilars.com
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost ...
5000×3333
www.centerforbiosimilars.com
CT-P13 Shows Similar Effectiveness, Safety in Biologic …
4630×2639
www.centerforbiosimilars.com
Study Compares Uptake, Prices of Biosimilars in US vs 2 European Countr…
5616×3744
www.centerforbiosimilars.com
Rituximab Biosimilar Plus Methotrexate Improves Outcomes …
3750×2063
www.centerforbiosimilars.com
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar ...
3840×2527
www.centerforbiosimilars.com
BioRationality: FDA Clarification Provides New Indications and Proc…
3840×2560
www.centerforbiosimilars.com
FDA Approves Pavblu for Retinal Conditions
5824×3264
www.centerforbiosimilars.com
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to ...
1000×530
www.centerforbiosimilars.com
Comparable Safety, Efficacy Between First Proposed Natalizumab ...
1000×667
www.centerforbiosimilars.com
ACR Supports Affordable Treatments, Use of Biosimilars …
5958×3648
www.centerforbiosimilars.com
Getting Rid of Clinical Efficacy Testing for Biosimilars Is Needed, …
5824×3264
www.centerforbiosimilars.com
Enoxaparin Biosimilar Shows Similar Efficacy to Originator in ...
6000×3000
www.centerforbiosimilars.com
ASCO Posters Reveal Successful Approaches to Biosimilar Adoption in ...
3840×2561
www.centerforbiosimilars.com
Biosimilar Etanercept Similar to Enbrel in Persistence of Treat…
1920×1080
www.centerforbiosimilars.com
The Top 5 Biosimilar Articles for the Week of September 16
5184×2917
www.centerforbiosimilars.com
BioRationality—The Missing Rationality in Biosimilar Discussions and ...
1200×675
www.centerforbiosimilars.com
Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market
3840×2560
www.centerforbiosimilars.com
Biosimilar Candidate CT-P43 Shows Biosimilarity With Ustekin…
5472×3648
www.centerforbiosimilars.com
Posters Show Efficacy for Combination Therapies With Tras…
8192×5407
www.centerforbiosimilars.com
Biosimilars Improve Access to Biologic Therapies, JAK Inhibitors for ...
1200×650
www.centerforbiosimilars.com
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF ...
3840×2224
www.centerforbiosimilars.com
ASCO Posters Reflect on Reimbursement Trends, Combination Therapies ...
某些结果已被隐藏,因为你可能无法访问这些结果。
显示无法访问的结果
报告不当内容
请选择下列任一选项。
无关
低俗内容
成人
儿童性侵犯
Invisible focusable element for fixing accessibility issue
反馈